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Background: Antipsychotic medications are commonly used to manage the behavioral and psychological
symptoms of dementia. Several large studies have demonstrated an association between treatment with
antipsychotics and increased morbidity and mortality in people with dementia.
Aims: To assess the effectiveness of interventions used to reduce inappropriate prescribing of antipsy-
chotics to the elderly with dementia in residential care.
Method: Systematic searches were conducted in 12 electronic databases. Reference lists of all included
studies and forward citation searching using Web of Science were also conducted. All quantitative studies
with a comparative research design and studies in which recognized methods of qualitative data
collection were used were included. Articles were screened for inclusion independently by 2 reviewers.
Data extraction and quality appraisal were performed by 1 reviewer and checked by a second with
discrepancies resolved by discussion with a third if necessary.
Results: Twenty-two quantitative studies (reported in 23 articles) were included evaluating the effec-
tiveness of educational programs (n ¼ 11), in-reach services (n ¼ 2), medication review (n ¼ 4), and
multicomponent interventions (n ¼ 5). No qualitative studies meeting our inclusion criteria were
identiﬁed. Eleven studies were randomized or controlled in design; the remainder were uncontrolled
before and after studies. Beneﬁcial effects were seen in 9 of the 11 studies with the most robust study
design with reductions in antipsychotic prescribing levels of between 12% and 20%. Little empirical
information was provided on the sustainability of interventions.
Conclusion: Interventions to reduce inappropriate prescribing of antipsychotic medications to people
with dementia resident in care homes may be effective in the short term, but longer more robust studies
are needed. For prescribing levels to be reduced in the long term, the culture and nature of care settings
and the availability and feasibility of nondrug alternatives needs to be addressed.
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Table 1
Master Search Strategy
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and
Ovid MEDLINE(R) <1946 to Present>
1 assisted living facilities/or group homes/or homes for the aged/or
nursing homes/or skilled nursing facilities/(35398)
2 (care adj (setting* or home* or residence* or facilit* or unit*)).ti,ab.
(103097)
3 long-term care.ti,ab. (12891)
4 LTCF.ti,ab. (227)
5 elderly care.ti,ab. (636)
6 geriatric care.ti,ab. (1130)
7 geriatric clinic*.ti,ab. (339)
8 (geriatric adj2 unit).ti,ab. (722)
9 communal care.ti,ab. (11)
10 institutional* care.ti,ab. (1440)
11 (residential adj (care or unit* or home*)).ti,ab. (2424)
12 nursing home*.ti,ab. (20297)
13 (dementia adj (unit* or home* or care)).ti,ab. (941)
14 or/1e13 (150033)
15 exp Dementia/(109677)
16 exp Alzheimer Disease/(60964)
17 dementia.ti,ab. (58425)
18 alzheimer*.ti,ab. (80216)
19 (cognitive adj (impairment or decline)).ti,ab. (28848)
20 BPSD.ti,ab. (401)
21 (agitated or agitation).ti,ab. (11407)
22 (depressed or depression).ti,ab. (242245)
23 (anxiety or anxious).ti,ab. (100546)
24 (aggressive* adj2 behav*).ti,ab. (11959)
25 (unsettled adj2 behav*).ti,ab. (11)
26 (difﬁcult adj2 behav*).ti,ab. (395)
27 residents.ti,ab. (58407)
28 or/15e27 (528228)
29 antipsychotic*.ti,ab. (23427)
30 neuroleptic*.ti,ab. (17905)
31 exp Antipsychotic Agents/(117101)
32 psychotropic*.ti,ab. (12422)
33 29 or 30 or 31 or 32 (137714)
34 14 and 28 and 33 (1025)
35 ((reduce* or reducing or reduction) adj4 (medication or drug*)).ti,ab.
(21110)
36 inappropriate prescribing.ti,ab. (446)
37 exp Inappropriate Prescribing/(329)
38 suboptimal prescribing.ti,ab. (59)
39 (inappropriate* adj3 (prescribed or prescriptions or medication or drug* or
antipsychotics or neuroleptics)).ti,ab. (1307)
40 35 or 36 or 37 or 38 or 39 (22890)
41 40 and 14 (659)
42 34 or 41 (1621)
J. Thompson Coon et al. / JAMDA 15 (2014) 706e718 707assessment to identify any treatable cause of symptoms (eg, hunger,
thirst, pain, infection, loneliness). Furthermore, underlying causes
should be treated and alternative nonpharmacological interventions
explored before the initiation of antipsychotics.4e6 Risperidone is the
only antipsychotic licensed in the United Kingdom for this indication,
and then only for short-term use. Nevertheless, other antipsychotic
agents are often prescribed and used on a long-term basis with
infrequent medication review.7 BPSD can cause signiﬁcant carer stress
to family members and care home staff that, without intervention,
may rapidly lead to acute hospital admission and/or transfer to a more
intensive care setting.8 Antipsychotic medicationmay be viewed as an
easier option than nonpharmacological alternatives, and the risks are
rarely discussed or documented. In 2013, the American Medical
Directors Association was involved in identifying the top 5 items that
physicians and patients should question in the long-term care setting
as part of the American Board of Internal Medicine Foundation’s
Choosing Wisely Campaign. Item 4 on this list was “Don’t prescribe
antipsychotic medications for behavioral and psychological symptoms
of dementia (BPSD) in individuals with dementia without an assess-
ment for an underlying cause of the behavior.”9
The most recent UK audit of primary care data showed a decrease
in antipsychotic prescribing to individuals with dementia from
approximately 17% in 2006 to 7% in 2011.10 The audit showed wide-
spread and signiﬁcant variation in practice across the country, ranging
from approximately 3% of individuals with dementia receiving anti-
psychotic medication at the time of the audit in London and the
southeast to approximately 13% in the northwest. The audit provided
no information on duration of prescription or on the residential
setting of people with dementia and represents data from approxi-
mately 50% of general practices in the United Kingdom. Audit studies
based in nursing homes have generally reported a higher prevalence
of antipsychotic prescription among individuals with dementia.11e14
Anecdotally, we are aware of a variety of interventions being used to
assess, evaluate, and review the prescription of antipsychotic medica-
tions in care homes. These include education and raising staff aware-
ness, development and use of decision-making pathways, medication
checklists, mood, pain and behavioral charts, advice on nondrug-based
alternatives, regular medication review by pharmacists, community
or hospital-based psychiatrists and general practitioners, interdisci-
plinary education programs, and pharmacist-led strategies.
The purpose of this systematic review was to assess the effec-
tiveness of interventions used to reduce inappropriate prescribing of
antipsychotic medications to individuals with dementia resident in
care homes to help to inform the provision of services. We also were
interested in published accounts of the views and experiences of
prescribers of included interventions to highlight barriers and facili-
tators to the successful implementation of such interventions.
Methods
The systematic review was conducted following the general
principles published by the NHS Centre for Reviews andDissemination
(CRD).15 A predeﬁned protocol was developed following consultation
with topic and methods experts and is registered with PROSPERO
(PROSPERO 2012:CRD42012003425).
Literature Search and Eligibility Criteria
Acomprehensive search syntaxusingMeSHand free text termswas
developed by an information specialist (M.R.) in consultationwith the
review team (Table 1). The strategy was developed for MEDLINE and
adapted as appropriate for the other searched databases (EMBASE,
Social Policy and Practice [including AgeInfo], and PsycINFO [via OVID],
CDSR and CENTRAL [via The Cochrane Library], CINAHL [viaEBSCOhost], AMED and British Nursing Index [via NHS Evidence], Sci-
ence Citation Index Expanded and Social Science Citation Index [via
Web of Science]). All databases were searched from inception to
November 2012. Update searcheswere run inNovember 2013. No date,
studydesign, or language restrictionswere imposed. The reference lists
of all included articles and identiﬁed review articles were checked for
additional relevant studies. Forward citation searching for each
included article was conducted using ISI Web of Knowledge.
We were interested in the effectiveness of interventions (eg, staff
training, regular medication review) designed to reduce inappropriate
prescription of antipsychotic medications to individuals with
dementia in community residential care settings. Interventions had
to be aimed at professionals (eg, general practitioners, community
psychiatrists, pharmacists) responsible for prescription of these
medications in these settings.We alsowere interested in reports of the
views and experiences of prescribers using the included interventions.
All quantitative studies reporting comparative data were included.
Qualitative studies using recognized methods of qualitative data
collection (eg, focus groups, interviews, and observation) and analysis
(grounded theory, narrative analysis, thematic analysis, discourse
analysis) were sought.
Fig. 1. Flow chart of study selection process.
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The search results were uploaded to reference management
software (Endnote X5, V5; Thomson Reuters, Philadelphia, PA). Titles
and abstracts were screened for relevance independently by 2 re-
viewers (J.T.C., M.R., or R.A.), with any disagreements being resolved
by discussion and involvement of a third reviewer (J.T.C., M.R., or R.A.)
where necessary. The full text of potentially relevant articles was
retrieved and screened in the same way using the prespeciﬁed in-
clusion and exclusion criteria. All duplicate articles were double-
checked and excluded.
Data Collection
For each study, details of the intervention, the characteristics of
those receiving it, the characteristics of the patient population
involved, the setting, the study methods, and outcomes relating to
medication use were recorded. Data were extracted by one reviewer
(J.T.C. or M.R.) into a data extraction form based on the Cochrane
Effective Practice and Organisation of Care Review Group Data Collec-
tion Checklist,16 which was piloted on several studies and reﬁned. The
Cochrane Effective Practice and Organisation of Care Review Group
Data Collection Checklist includes a taxonomy of intervention com-
ponents,whichwas completed foreach trial aspartof this process.Data
were collected from published articles only; manuals were not
requested from trial authors. All data extraction was checked by a
second reviewer (J.T.C. or M.R.) with discrepancies resolved by dis-
cussion and involvement of a third reviewer (R.A.) where necessary.
Risk of Bias
The quality of all included studies was appraised by one reviewer
(J.T.C.) and checked by a second (M.R., R.A., or R.W.). In an amendment
to the published protocol, all articles were appraised using the
Effective Public Health Practice Project tool17 to enable assessment of
all study designs with the same rubric. Appraisal considered the
method of sample selection, potential for bias connected with study
design, differences between groups at baseline and how these were
dealt with in the analysis, assessment of outcome measures,
description of the ﬂow of patients through the study, and use of a
valid and reliable primary outcome measure.
Data Synthesis
Changes in medication use were reported in all included studies.
However, the multitude of different formats in which the data were
provided and the range of included study designs precluded formal
pooling of the data. For example, among the randomized studies,
medication use was variously reported as psychoactive drug use
score, proportion of residents who had antipsychotic medications
discontinued, number of days of antipsychotic therapy per patient per
month, proportion of residents taking antipsychotic medications, and
dose of antipsychotic medication. Data were therefore tabulated,
grouped according to study design and outcome, and discussed
narratively.
Results
The electronic searches retrieved a total of 5071 unique citations.
Screening of title and abstracts against the inclusion and exclusion
criteria resulted in the retrieval of the full text of 80 articles. Fifty-
nine articles were excluded because the following aspects of the
article did not meet the inclusion criteria: population (n ¼ 3), inter-
vention (n ¼ 14), reported outcomes (n ¼ 1), and study design(n ¼ 32). Six articles were published as conference abstracts only
with insufﬁcient information provided and we were unable to locate
a full-text publication despite contact with authors, and 3 were
duplicate publications. One additional article was located through
hand searching of the bibliographies of identiﬁed systematic review
articles. The update search identiﬁed an additional 985 articles, of
which 7 were retrieved in full text and 1 article met the inclusion
criteria. A total of 23 articles were included, describing 22 studies.
Figure 1 shows the ﬂow of studies through the review. Table 2 shows
the study characteristics of all included articles. All the included
studies provided quantitative data. We did not identify any articles
reporting the views and experiences of prescribers with speciﬁc in-
terventions. Our search identiﬁed a number of qualitative articles
exploring factors that inﬂuence prescribing practice in care homes;
these are considered further in the discussion.
Study Characteristics
Six of the studies are randomized,14,18e22 5 have a controlled
design,23e28 and 11 are uncontrolled before and after studies.29e39 The
studies were published between 1987 and 2013 andwere conducted in
the United States (n ¼ 8), the United Kingdom (n ¼ 5), Canada (n ¼ 5),
Australia (n ¼ 2), Norway, and Sweden. Very little demographic infor-
mation was provided about the people (physicians, nurses, pharma-
cists, and so forth) who received the interventions and in most studies
it is not clear howmany prescribers were involved. The studies ranged
in size from 21 to 7000; approximately 19,300 people with dementia
were included in total (information not provided in all studies).
Intervention Characteristics
Descriptions of the interventions used in the studies are shown in
Table 3. We grouped studies according to intervention type using 4
Table 2
Characteristics of Included Studies
Source; Country;
Study Design
Setting Delivered by Delivered to Patients Frequency and Duration of
Intervention
Length of
Follow-up,
mo
Relevant Outcomes
Educational programs e randomized and controlled study designs (n ¼ 7)
Testad, 201018;
Norway; RCT
Nursing homes
n ¼ 2 [I]
n ¼ 2 [c]
Educators All care staff, including
leaders and domestic staff
n ¼ 197
All residents with dementia
n ¼ 75 [I]
n ¼ 70 [c]
2-day seminar and monthly
guidance groups for 6 mo
6 Proportion of residents taking
AP medication
Changes in dose of AP
medication
Fossey, 200614;
UK; cRCT
Dementia nursing
homes
n ¼ 6 [I]
n ¼ 6 [c]
Psychologist, occupational
therapist or nurse
supported by research
team
Care home staff
n ¼ not reported
All residents
n ¼ 168 [I]
n ¼ 181 [c]
2 days a week for 10 mo 10 Proportion of residents taking
antipsychotics
Dose of antipsychotics
Meador,199719;
USA; RCT
Nursing homes
n ¼ 6 [I]
n ¼ 6 [c]
1. Old-age psychiatrist
2. Trained nurse educator
3. Home management
specialist
4. Reference card and
manual
All nursing home care
providers including
physicians, nurses,
nursing assistants and
other direct care staff,
administrators and
families
n ¼ not reported
All residents older than
65 years and resident for
more than 6 months
n ¼ 680 [I]
n ¼ 631 [c]
1. 45e60-min visit to
physicians with more
than 5 residents
2. 5 or 6 x 1 hour
sessions for nursing
staff over a 1-wk
period; follow-up
session after 4 wk;
evening meeting with
families
3. 4-hour consultation with
administrative staff
4. Provided to all staff
6 Medication use in days per 100
Avorn, 199220;
USA; cRCT
Nursing homes
n ¼ 6 [I]
n ¼ 6 [c]
1. Mail drop
2. Clinical pharmacist
Physicians, nurses, nursing
assistants and aides
n ¼ not reported
All residents
n ¼ 431 [I]
n ¼ 392 [c]
1. 3 mailings
2. 3 interactive visits
with each physician; 4
training sessions with
nurses and nursing
assistants; 1 training
session for nurses on
night shift
5 Psychoactive drug use score
Proportion of residents who
discontinued AP medications
Number of days of
antipsychotic therapy per
patient per month
Hagen, 200523;
Canada; cITS
Long-term care
facilities
n ¼ 12 [I]
n ¼ 12 [c]
1. Trained study pharmacist
2. Laminated reference card
3. Posters and word of mouth
4. Trained registered nurses
Physicians (n ¼ 49/84),
nurses (n ¼ 195/250),
facility pharmacists
(n ¼ 12/12) and family
members
All resident
n ¼ 1190 [I]
n ¼ 1124 [c]
1. 1 session (30 min) for
physicians; 2 sessions
(30e45 min) for
nursing staff; 1 session
for pharmacists (30 min)
2. Provided to all staff
3. Provided in each unit
4. 1 session (45 min) for
family members
12 Proportion of residents
receiving antipsychotics
Ray, 199324;
USA; CCT
Nursing homes
n ¼ 2 [I]
n ¼ 2 [c]
1. Old-age psychiatrist
2. Reference card/manual
3. Trained nurse educator
4. Nursing home
management specialist
Physicians, nurses, nursing
assistants, administrators
and families
n ¼ not reported
All residents
n ¼ 228 [I]
n ¼ 218 [c]
1. 1 session for physicians
(45e60 min)
2. Provided to all staff
3. 6 sessions (60 min) over
3-week period for
nursing home staff
(1 session each); follow-
up session 4 weeks later;
1 evening session for
family members
4. 1 session (240 min) for
home’s administrator
4 Medication use e days per 100
Proportion of residents
withdrawn from antipsychotic
medications
(continued on next page)
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Table 2 (continued )
Source; Country;
Study Design
Setting Delivered by Delivered to Patients Frequency and Duration of
Intervention
Length of
Follow-up,
mo
Relevant Outcomes
Ray, 198725;
USA; CCT
Nursing homes
n ¼ not reported
Trained physician counselor Most frequent physician
prescribers of
antipsychotics within
3 geographical areas
n ¼ 45 [I]
n ¼ 136 [c]
All residents
n ¼ 2428 [I]
n ¼ 4579 [c]
1 visit (15 min) 12 Proportion of residents receiving
antipsychotic medication
Dose of antipsychotic medication
Proportion of new
antipsychotic drug users
Proportion of chronic
antipsychotic drug users
Educational programs e before and after study designs (n ¼ 4)
Monette 201329;
Canada; BA
Long-term care
center n ¼ 2
1. Letters, posters and
newsletters
2. Trained in-house nurse
3. Old-age psychiatrist
4. Pamphlet
5. Reminder memo
Prescribing physicians,
pharmacists, nursing
staff, and personal care
attendants
n ¼ 370
All residents with dementia
n ¼ 293
1. 1 mailing
2. 1 session (90 min) for
nursing staff and
(60 min) for personal
care attendants
3. 1 session for
physicians and
pharmacists (90 min)
4. Provided in each unit
5. Monthly memo
6 Proportion of antipsychotic
users
Vida, 201230;
Canada; BA
Long-term care
center n ¼ 1
1. Researchers
2. Written reference materials
Prescribing physicians and
nursing staff
n ¼ not reported
All residents with dementia
n ¼ 308
1. 2 lectures (60e90 min)
2. Provided to all staff
5 Proportion of residents who had
dose reduced
Proportion of residents who had
antipsychotic medication
withdrawn
Monette, 200831;
Canada; BA
Nursing home
n ¼ 1
1. Letters, internal journal and
posters
2. Researcher
3. Old-age psychiatrist
4. Pamphlet
5. Reminder memo
Physicians/pharmacists
(n ¼ 6/6), personal care
assistants (n ¼ 86/123),
nursing staff (74/93)
All residents with a
diagnosis of dementia
receiving AP medication
n ¼ 90
1. 1 mailing
2. 1 session (90 min) for
nursing staff and (45
min) for personal care
attendants
3. 1 session for physicians
and pharmacists (90 min)
4. Provided in each unit
5. Monthly memo
7 Proportion of residents who had
dose reduced
Proportion of residents who had
antipsychotic medication
withdrawn
Earthy, 200032;
Canada; BA
Long-term care
facility
n ¼ 1
1. Researchers
2. Written information
Admitting physicians,
nurses, rehabilitation
staff, social workers,
dietary and pharmacy
staff
n ¼ not reported
All residents
n ¼ 198
1. Not reported
2. Not clear
6 Proportion of residents
receiving antipsychotic
medication
In-reach services e randomized and controlled study designs (n ¼ 2)
Schmidt, 199821;
Sweden; RCT
Nursing homes
n ¼ 18 [I]
n ¼ 18 [c]
Community pharmacists Nursing home physicians
and nursing personnel
n ¼ not reported
All long-term residents
n ¼ 626 [I]
n ¼ 1228 [c]
1 d/mo 12 Reduction in prescription of
antipsychotic medications
Ballard, 200226;
UK; CCT
Nursing and
residential care
facilities
n ¼ 6 [I]
n ¼ 3 [c]
1. Full-time psychiatric nurse
supervised by a consultant
old-age psychiatrist
2. Clinical psychologist
Psychiatric liaison team
reviewed patients
directly and also provided
support to facility staff
n ¼ not reported
All residents with dementia
n ¼ 208 [I]
n ¼ 125 [c]
1. 2 sessions per wk
2. 1 session per wk
9 Reduction in antipsychotic use
Medication review e randomized study designs (n ¼ 1)
Patterson 201022;
UK; cRCT
Nursing homes
n ¼ 11 [I]
n ¼ 11 [c]
Study pharmacists Nursing home prescribers
(general practitioners)
n ¼ not reported
All residents over the age of
65 who gave informed
consent
n ¼ 173 [I]
n ¼ 161 [c]
1 visit per mo 12 Proportion of residents taking
inappropriate psychoactive
medication
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Medication review e before and after study designs (n ¼ 3)
Morrison, 200933;
UK; BA
Nursing homes
n ¼ 3
General practice computer
system
Multidisciplinary primary
health care team and
nursing home staff
n ¼ not reported
All nursing home residents
registered with one GP
practice
n ¼ 81
Initial meeting and then
reminder to use at
subsequent meetings
every 6 mo
6 Proportion of residents receiving
antipsychotic medication
Dahl, 200834;
USA; BA
Dementia-speciﬁc
long-term care
facility
n ¼ 1
Quality Improvement (QI)
Team using Psychotropic
Assessment Tool (PAT)
Nursing home staff,
families, social workers,
consulting pharmacist,
medical director, geriatric
fellow, resident nurse
manager, and
administrators
n ¼ not reported
All residents
n ¼ 110
At 2 of 4 quarterly family
conference meetings;
discussed at subsequent
QI meeting
12 Proportion of residents receiving
antipsychotic medication
Schultz, 199135;
USA; BA
Dementia care unit
within a long-term
care facility
n ¼ 1
Psychoactive medication review
team (consultant old age
psychiatrist, pharmacist and
clinical psychologist)
n ¼ not reported
Facility staff
n ¼ not reported
All residents on the
dementia care unit
n ¼ 38
Not clear 12 Proportion of residents receiving
psychoactive medication
Multicomponent interventions e controlled study designs (n ¼ 1)
Westbury, 201027
and 201128;
Australia; CCT
Nursing homes
n ¼ 13 [I]
n ¼ 12 [c]
1. Mail drop
2. Laminated guidelines
3. Well-known old-age
psychiatrist
4. Researchers
5. Community pharmacists
6. Newsletters
7. Pamphlet
Physicians, community
pharmacists, nursing
staff, residents and their
families
n ¼ not reported
All residents
n ¼ 863 [I]
n ¼ 715 [c]
1. Mailing
2. Provided to all homes
3. Lecture on one occasion
4. Two days’ training for
pharmacists; 1 session
for nursing home
physicians
5. Two sessions for nursing
home staff
6. Provided to all homes
7. Available for all families/
residents
6 Proportion of residents receiving
antipsychotic medication
Multi-component interventions e before and after study designs (n ¼ 4)
Chakraborty,
201236; UK; BA
EMI care homes
n ¼ 6 at baseline
n ¼ 7 at re-audit
Psychiatrists and in-reach
mental health nurses
n ¼ not reported
Psychiatric liaison team
reviewed patients
directly and also provided
support to facility staff
n ¼ not reported
All residents with dementia
n ¼ 137 at baseline n ¼ 174
at re-audit
Regular visits Not clear Proportion of residents receiving
antipsychotic medication
Khan, 201137;
UK; BA
Nursing homes
with high level
of referrals
n ¼ 4
Doctors (n ¼ 3)
Community psychiatric nurses
(n ¼ 4)
Psychologist
Psychiatric liaison team
reviewed patients
directly and also provided
support to facility staff
n ¼ not reported
All patients of a community
mental health team
resident in one of the
care homes
n ¼ not clear
1 session per mo 6 Proportion of residents who
had dose of antipsychotic
medication reduced
Proportion of residents who
had antipsychotic
medication discontinued
Heal, 199838;
Australia; BA
Dementia-speciﬁc
nursing home
n ¼ 1
Not clear Nursing home staff
including unit manager,
physician, pharmacist,
and divisional therapist
n ¼ not reported
All residents
n ¼ 21
Not clear Not clear Proportion of residents taking
psychotropic medication
Rovner, 199239;
USA; BA
Nursing homes
n ¼ 17
1. Mail drop
2. In-service education
providers unclear
Nurses and physicians
(n ¼ not clearly reported)
All residents
n ¼ 2709
1. 1 mailing
2. Frequency and
intensity of in-service
education unclear
3 Proportion of residents receiving
antipsychotic medication
AP, antipsychotic; BA, before and after study; c, control; CCT, controlled clinical trial; cITS, controlled interrupted time series; cRCT, cluster randomized clinical trial; GP, general practitioner; I, intervention; RCT, randomized
clinical trial.
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Table 3
Intervention Descriptions (Summary Using EPOC Data Collection Checklist)
J. Thompson Coon et al. / JAMDA 15 (2014) 706e718712categories: educational programs (n ¼ 11 studies), in-reach services
(n ¼ 2 studies), medication review (n ¼ 4 studies), and multicom-
ponent interventions (n ¼ 5 studies). The EPOC Data Collection
Checklist includes a taxonomy of intervention components grouped
under 4 headings: professional, organizational, structural, and
regulatory.16 The interventions within studies of educational
programs14,18e20,23e25,29e32 consisted mainly of professional compo-
nents, such as educational meetings, distribution of educational
materials, and educational outreach. In-reach services21,26 contained
mainly organizational and structural components. Studies containing
the most variety were those in the medication review22,33e35 and
multicomponent intervention groups27,28,36e39 incorporating educa-
tional, organizational, structural, and regulatory interventions. In
many cases, there was insufﬁcient information provided in the article
to replicate the intervention in another setting.
Using the EPOC Data Collection Checklist classiﬁcation, the number
of intervention components per study ranged from1 to 7;most studies
consisted of 3. The most frequently used intervention component was
educational outreach (14 studies), and this was evident across all 4
types of intervention. Educational outreach was deﬁned as the use of a
trained person who met with providers in their practice settings to
give information with the intent of changing the provider’s practice.Study Quality
Assessment of the quality of each included study is shown in
Table 4. The global assessment of just over a third of the studies was
moderate or strong. Themain areas of weakness were in the collection
of primary outcome data and in the reporting of withdrawals anddropouts. In most of the studies, the outcome assessor was aware of
the intervention status of participants and the study participants
(prescribers) were aware of the research question. Although data on
prescribing rates were taken from patient and pharmacy records in
many cases, the data-collection process was performed by one indi-
vidual with no procedure for checking accuracy. Furthermore, the
data-collection tool was often not described, precluding judgment on
the validity of the measure. In most studies, there was little informa-
tion provided on the numbers of and reasons for withdrawals and
dropouts of either prescribers or patients. In Table 4 we have assessed
reporting of withdrawal and dropouts of patients; the reporting of the
ﬂow of prescribers was assessed as weak in all but 5 studies.14,21,24,31,33Medication Use
Educational programs (randomized and controlled study designs
n ¼ 7)
Despite considerable differences in the nature and
implementation of the educational programs used, introduction of a
program to enhance the management of BPSD behaviors and
improve appropriate prescribing of antipsychotic medications had
beneﬁcial effects in all 4 randomized studies14,18e20 and in 1 of the
controlled studies.24 Four of the 5 showed a reduction in medica-
tion use in the intervention group compared with the control group
of between 12% and 20%.14,19,20,24 Although Testad and colleagues18
reported no signiﬁcant differences between groups in the change in
proportion of residents taking antipsychotic medication, this was
against a background of reductions in restraint use and agitation
(Table 5).
Table 4
Indicators of Study Quality
B&A, before and after; CCT, controlled clinical trial; N/A, not applicable; RCT, randomized clinical trial.
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remaining studies.23,25 These are the largest studies within the review
in terms of the number of patients that the interventionwas ultimately
aimed at, although the number of physicians receiving training was
relatively low, and in the studybyRayandcolleagues,25 trainingwasnot
offered to nursing andother carehome staff. Explanations for the lack of
effect offered by the authors of these articles include the simultaneous
introduction andpromotion of the use of atypical antipsychotics during
the study period,23 a reﬂection of the wide variation in antipsychotic
prescribing in care homes over time,23 and barriers to reducing anti-
psychotic prescribing such as the increased time commitment neces-
sary to implement alternative methods of behavior management.25
Educational programs (before and after study designs n ¼ 4)
The results from these studies are more difﬁcult to interpret, as it
is not clear what other factors inﬂuenced prescription rates over the
study period. Results showed similar trends to those seen in studies
of a more robust design. These are smaller single30e32 or 2-center
studies29 involving between 53 and 300 patients and their associ-
ated care staff. The interventions resulted in a decrease in antipsy-
chotic use (variously reported) in 3 studies.29e31 The baseline level of
antipsychotic use in the study reported by Earthy and colleagues32
was low and little changed by the intervention (increased from 17%
to 19%). However, the authors report improvements in documenta-
tion, a reduction in administration of “as-needed” medication by
nursing staff and a decrease in the frequency of problem behaviors.
In-reach services (randomized and controlled study designs n ¼ 2)
Both of these studies involved improved multidisciplinary team-
work either with a psychiatric team26 or a pharmacist21 spending timeworking at care homes supporting the care home staff. In both studies,
there were statistically signiﬁcant reductions in prescription rates
associatedwith the intervention (19%; P¼ .00721 and 16%; P< .000126);
however, reductions also were seen in the control groups in both
studies partly21 or wholly26 negating the impact of the intervention.
Medication review (randomized [n ¼ 1] and before and after study
designs [n ¼ 3])
The study reported by Patterson and colleagues22 provides the
most robust evidence of the effectiveness of this approach to
reducing inappropriate prescribing. The intervention used was also
the most sophisticated and used an element of in-reach as well as
medication review, with specially trained pharmacists visiting
intervention homes monthly for 12 months to review prescribing
information and guide prescribing decisions. The authors reported a
signiﬁcant difference between intervention and control homes in
the proportion of residents taking inappropriate antipsychotic
medications (20% vs 50% [odds ratio ¼ 0.26; 95% conﬁdence interval
0.14e0.49]). The design of the remaining 3 studies permits the
consideration of trends in results only. Two used audit and feedback
and reminders to review medication needs on a regular basis33,34
and these resulted in minimal changes in prescribing rates.
The ﬁnal study was conducted against a background of changes in
accommodation conditions for the residents such that they were
moved into a specialized, secure dementia unit. Perhaps unsur-
prisingly, prescription rates were reduced from the extremely high
(95% of residents receiving antipsychotic medication) to a much
lower proportion (58%), although it is not possible to determine
whether this was due to the change in accommodation or the
intervention.
Table 5
Summary of Medication Use Outcomes
Source n (at Baseline) Outcome Measure Level at Baseline Level Post Intervention Effect on Outcome
Educational programs - randomized and controlled study designs
Testad 201018 44 [I]
46 [c]
Proportion of residents taking antipsychotic medication 28% [I]
9% [c]
29% [I] at 6/12
14.3% [c] at 6/12
Medication use remained relatively unchanged at both 6/12
and 12/12.
No statistically signiﬁcant differences between groups.32% [I] at 12/12
8.7% [c] at 12/12
Fossey, 200614 181 [I]
168 [c]
Proportion of residents taking antipsychotics 47% [I]
50% [c]
23 [I] at 12/12
42 [c] at 12/12
Reduction in medication use in the intervention group.
Mean difference between groups 19.1%; 95% CI 0.5%e37.7%.
Median dose of antipsychotics (in chlorpromazine
equivalents)
100 [I]
100 [c]
102.1 [I] at 12/12
107.1 [c] at 12/12
No signiﬁcant difference in median dose of anti-psychotics
Mean difference between groups 4.9 (20.0e29.9; P ¼ .67)
Meador, 199719 680 [I]
631 [c]
Medication use (days per 100) 25.3  2.5 [I]
26.2  1.7[c]
19.7 1.7 [I] at 6/12
26  2.5 [c] at 6/12
Reduction in medication use in the intervention group
Mean difference between groups 23% (0.014).
Avorn, 199220 431 [I]
392 [c]
Psychoactive drug use score 1.87 [I]
1.74 [c]
1.36 [I]
1.60 [c]
Reduction in psychoactive drug use score
Mean difference in risk reduction 0.37; 95% CI 0.08
to 0.67; P ¼ .02
Proportion of residents who discontinued antipsychotic
medication use
-
-
32% [I]
14% [c]
Greater proportion in the intervention group
Mean difference between groups 18%; 95% CI 3% to 33%
Number of days of antipsychotic therapy per patient per
month
Not reported ⇩7.1 [I]
⇩3.7 [c]
Greater reduction in the intervention group
Mean difference between groups 3.5 d; 95% CI 10.6 to 3.6
Hagen, 200523 1666 [I]
648 [c]
Proportion of residents taking neuroleptic medication 17% [I]
19% [c]
24% [I]
27% [c]
Small increase in medication use in both groups
No signiﬁcant differences between groups
Ray, 199324 228 [I]
218 [c]
Medication use (days per 100) 29.2  3.2 [I]
28.6  3.2 [c]
Reduced by 21 days/100 [I]
Reduced by 4 days/100 [c]
Reduction in medication use in the intervention group
Mean difference between groups 59%; P < .01
Proportion of residents who discontinued antipsychotic
medication
-
-
30/44 withdrawn [I]
7/59 withdrawn [c]
Greater reduction in the intervention group
Mean difference between groups 12%; P < .01
Ray, 198725 Not clear Residents taking antipsychotic medication
(weighted average per 100 pts seen)
22.0 [I]
14.5 [c]
21.7 [c]
14.5 [c]
No signiﬁcant difference in any of the four indices of
prescribing rate
Mean antipsychotic drug dose (gram- equivalents)
(weighted average per 100 pts seen)
670 [I]
340 [c]
920 [I]
320 [c]
New antipsychotic drug users
(weighted average per 100 pts seen)
5.1 [I]
4.5 [c]
4.8 [I]
3.2 [c]
Chronic antipsychotic drug users
(weighted average per 100 pts seen)
12.8 [I]
6.2 [c]
11.1 [I]
5.5 [c]
Educational program e before and after study designs
Monette, 201329 293 Proportion of residents taking antipsychotic medication 44% 38% at 12/12
40% at 16/12
Reduction in medication use during the program; reduction was
not maintained postprogram in both centers.
During the intervention - odds ratio 0.943 per week in Center
A (95% CI 0.921e0.965) and 0.969 per week in Centre B
(95% CI 0.944e0.994)
Vida, 201230 53 Proportion of residents who had the dose of antipsychotic
medication reduced
- 15.2% Reduction in medication use during the intervention.
Proportion of residents who discontinued antipsychotic
medication
- 21.7%
Monette, 200831 90 Proportion of residents who discontinued antipsychotic
medication
- 49.4% Reduction in medication use during the intervention.
Proportion of residents who had the dose of antipsychotic
medication reduced
- 13.6%
Earthy, 200032 198 Proportion of residents taking neuroleptic medication 17% 19% No signiﬁcant difference in medication use.
In-reach services e randomized and controlled study designs
Schmidt, 199821 626 [I]
1228 [c]
Proportion of residents taking antipsychotic medication 40.1% [I]
37.6% [c]
32.6% [I]
34.9% [c]
Greater reduction in medication use in the intervention homes
compared with baseline.
19% reduction (P ¼ .007) intervention.
7% reduction (P ¼ .176) control.
Ballard, 200226 208 [I]
125 [c]
Proportion of residents taking neuroleptic medication 44% [I]
41% [c]
28% [I]
33% [c]
Signiﬁcant reductions in each group compared with baseline but
no signiﬁcant difference between groups
J.Thom
pson
Coon
et
al./
JA
M
D
A
15
(2014)
706
e
718
714
Medication review e randomized study designs
Patterson, 200822 173 [I]
161 [c]
Proportion of residents taking inappropriate psychoactive
medication
Greater reduction in medication use in the intervention group
20% vs 50% (odds ratio ¼ 0.26; 95% CI 0.14e0.49).
Medication review e before and after study designs
Morrison, 200933 81 Proportion of residents taking antipsychotic medication 27% 19% Reduction in medication use during the intervention.
Dahl, 200834 110 Proportion of residents taking antipsychotic medication 26.5% 25.2% No change in medication use during the intervention.
Schultz, 199135 38 Proportion of residents taking psychoactive medication 95% 58% Reduction in medication use during the intervention.
Proportion of residents who had the dose of psychoactive
medication reduced
- 42%
Multicomponent interventions e controlled study designs
Westbury, 201027, 201128 863 [I]
715 [c]
Proportion of residents taking antipsychotic medication 20.3% [I]
21.9% [c]
18.6% [I] at 6/12
23.9% [c] at 6/12
Greater reduction in medication use in the intervention homes
during the intervention.
Difference between intervention and control P < .05.
20% [I] at 18/12
18.9% [c] at 18/12
12 months after the end of the intervention; medication use
returned to preintervention levels in the intervention group
but decreased markedly in the control group.
Proportion of residents who had the dose of antipsychotic
medication reduced or discontinued
- 36.9% [I]
20.9% [c]
Greater proportion of residents had the dose of antipsychotic
medication reduced or discontinued in the intervention group.
Difference between intervention and control P < .01.
Multicomponent interventions e before and after study designs
Chakraborty, 201236 137 Proportion of residents taking antipsychotic medication 29.5% [RH]
57.1% [NH]
11.5% [RH]
43.7% [NH]
Reduction in medication use in both nursing and residential
homes during the intervention.
Khan, 201137 63 Proportion of residents who had the dose of antipsychotic
medication reduced
- 10% Reduction in medication use during the intervention.
Proportion of residents who discontinued antipsychotic
medication
- 16%
Heal, 199838 21 Proportion of residents taking psychotropic medication 72% 28% Reduction in medication use during the intervention.
Rovner, 199239 2707 Proportion of residents taking neuroleptic medication
(mean [SD])
25.4% 15.9% at 3/12 Reduction in medication use during the intervention.
Difference compared to baseline (P < .0001).
13.5% at 12/12 The reduction in medication use was maintained at 9 months after
the end of the intervention period.
C, control; CI, conﬁdence interval; I, intervention; NH, nursing home; pts, patients; RH, residential home.
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after study designs [n ¼ 4])
The 5 studies using multicomponent interventions ranged in
complexity from a study involving 3 components, audit and feedback,
continuity of care, and change to the site of service delivery36 to 7
components incorporating education, audit and feedback, and
structural changes.27,28 Studies also varied widely in size, and were
implemented in between 1 and 25 homes. All studies showed re-
ductions in prescription rates (ranging from 5% to 66%) associated
with the intervention, although only the study reported by Westbury
and colleagues was controlled.27,28
Long-term effects of interventions
Only 4 studies assessed whether changes to prescription levels
achieved during the intervention period were maintained. Two
studies reported a return to baseline antipsychotic prescription
levels.27e29 Testad and colleagues18 reported that medication levels
remained constant 6 months after the end of the intervention. Finally,
Rovner and colleagues39 reassessed psychotropic drug use 9 months
after the end of the study period and found the effects in the inter-
vention on prescription rates had been maintained. Detail is sparse
because these follow-up visits were outside of the formal trial period,
but it is likely that the extent to which procedures used during the
study continued to be used varied between sites both within the
same trial and between trials. For example, Monette and colleagues29
commented that although staff at the long-term care centers had
expressed an intention to adopt some of the program components,
none were systematically adopted after the study. In contrast, Rovner
and colleagues39 attribute the maintenance of the effect of the
intervention in their study to an ongoing requirement for physicians
to complete an “indications and side effects” document for each
resident receiving psychoactive medication.39
Discussion
Principal Findings
This is the ﬁrst systematic review to speciﬁcally synthesize evi-
dence of the effectiveness of interventions to reduce inappropriate
prescribing of antipsychotics to people with dementia resident in care
homes. Irrespective of the nature of the intervention, in the studies
with the most robust design, antipsychotic prescription rates were
seen to fall as a result of the intervention. Although, more difﬁcult to
interpret, similar effects were also seen in the less well-designed
studies. There is little information in the included studies to aid
understanding of the sustainability of the effects of interventions.
Furthermore, one of the striking features of this body of literature is
that it spans 27 years, with the earliest trial reported in 1987. Over
this period, there have been a variety of initiatives, including changes
in regulations and widely disseminated guidance aimed at limiting
the use of these agents, but evidently prescribers still ﬁnd compelling
reasons to use them.
Results in Context
This work highlights 2 key issues that have been illustrated in
previous systematic reviews of related areas: (1) the challenges of
changing practice within care homes and (2) the scarcity of good-
quality research conducted in this setting. This body of literature
spans an extended time period during which research and reporting
methods have improved considerably; however, 6 of the included
before and after studies were conducted within the last 4 years. We
speciﬁcally searched for qualitative information on the views and
experiences of prescribers using the included interventions, butdisappointingly were unable to locate any articles meeting our in-
clusion criteria. Studies exploring factors that inﬂuence prescribing
behavior more generally suggest a variety of factors may be involved.
These include shortfalls in time, stafﬁng levels, and staff training that
impact on nonpharmacological alternatives to antipsychotic medi-
cation being considered viable, a pressure from family members and
carers to prescribe and a misconception of the likelihood that an
individual might beneﬁt from antipsychotic medication.40e44 Other
studies that have looked at implementation of interventions for other
purposes in care home settings have identiﬁed the importance of
involving family members in decision-making in the successful
management of behavioral problems45 and the management of
incontinence.46 A systematic review of the implementation of psy-
chosocial interventions for people with dementia in care homes
found that active engagement of care-home staff and family members
played a crucial role in successful implementation.47 Similarly, sys-
tematic reviews on the more general topic of improving prescribing
practice in care homes48e53 also have been unable to make clear
recommendations for future practice due to the varied nature of the
design, interventions, outcomes, and results49,50,53 and the poor
quality of included studies.48,51,52
Strengths and Limitations of Our Study
This systematic review followed best practice guidelines for sys-
tematic reviews,15 is reported according to the PRISMA statement,54
and is the ﬁrst in this topic area. Extensive electronic searches that
were not limited by date, study design, or language were augmented
with forward and backward citation searching of all included articles,
and authors of conference abstracts were contacted for their data,
where possible. We are, therefore, conﬁdent that this review
encompasses most if not all the available data on this topic.
We focused the review on one outcome measure, change in
medication use, but were unable to perform a meta-analysis of the
randomized clinical trials because of the variety of formats in which
these data was presented. This is undoubtedly a limitation of the
review but given the uniformity of the direction of the effect in most
of the studies, the small number of randomized clinical trials iden-
tiﬁed, and the accompanying variation and complexity in the
interventions used, it is unlikely that a pooled result would provide
any more useful insight than the synthesis we present. Although the
results of the before and after studies are difﬁcult to interpret, as
there may have been other inﬂuences on prescribing during the study
period, they provide a full picture of the spectrum of interventions
that have been evaluated and add weight to the evidence, as
interventions implemented in less tightly controlled conditions also
may have produced positive results. We had hoped to explore in more
depth whether speciﬁc attributes or implementation approaches
impacted on the effectiveness of interventions. Because of the rela-
tively small number of robust studies within each category and
the lack of reported detail, this was not possible, although we have
used a recognized method of characterizing the components of in-
terventions16 to provide the reader with as much detail as possible.
Implications for Practice and Research
The overall picture is one in which it would seem that the current
guidelines to limit antipsychotic prescribing are difﬁcult to imple-
ment in the day-to-day reality of practice, whilst juggling ethical
concerns, stafﬁng levels, staff competence with nonpharmacological
alternatives, and the wishes of distressed relatives and carers. Large,
good quality, well-reported, randomized research within the care
home setting with accompanying process evaluations would enable a
better understanding of the environment and its impact on successful
J. Thompson Coon et al. / JAMDA 15 (2014) 706e718 717implementation of interventions. Further qualitative work to explore
the barriers and facilitators to the appropriate prescription of anti-
psychotic medications will support efforts to achieve sustained
change in the varying speciﬁc contexts of individual care and nursing
homes.
Conclusions
Interventions to reduce inappropriate prescribing of antipsychotic
medications to people with dementia resident in care homes may be
effective in the short term, but longer-term, more robust studies are
needed. For prescribing levels to be reduced in the long term, the
culture and nature of care settings and the availability and feasibility
of nondrug alternatives needs to be addressed.
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